Skip to main content

Table 3 Independent factors that were associated with treatment response at week 48(non-response vs response) in CHB children using multivariate logistic regression analysis

From: The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B

Items

Variables

OR(95%CI)

B

P

HBeAg serological response

Initial drug (IFN vs ETV)

4.468(1.135, 17.583)

1.497

0.032

ALT/ULN

1.268(1.053, 1.527)

0.237

0.012

baseline log10HBsAg

0.220(0.068, 0.715)

−1.514

0.012

Age(<6y vs ≥6y)

6.177(1.539, 24.786)

1.821

0.010

Virological response

Initial drug (IFN vs ETV)

0.222(0.052, 0.956)

−1.506

0.043

Biochemical response

Initial drug (IFN vs ETV)

0.128(0.027, 0.614)

−2.057

0.010

HBsAg serological response

Initial drug (IFN vs ETV)

2953.434(1.302, 6,702,066.994)

7.991

0.043

baseline log10HBsAg

0.008(0.000, 0.506)

−4.816

0.022

Age(<6y vs ≥6y)

659.807(1.371, 317,523.678)

6.492

0.039

  1. OR Odds ratio, CI Confidence interval, ETV Entecavir, PegIFN Pegylated interferon, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ULN Upper limit of normal, HBV Hepatitis B virus, HBsAg Hepatitis B surface antigen, HBeAg Hepatitis B envelop antigen